Arcutis Biotherapeutics (ARQT) Gross Margin (2022 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Gross Margin of 90.72% for Q1 2026, up 455.0% year-over-year from 16.35% in Q1 2025, and little changed quarter-over-quarter from 90.97% in Q4 2025.
Arcutis Biotherapeutics (ARQT) Gross Margin (2022 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Gross Margin history runs 5 years deep, the most recent figure standing at 90.72% for Q1 2026.
- In Q1 2026, Gross Margin rose 455.0% year-over-year to 90.72%; the TTM figure through Mar 2026 stood at 90.94% (up 277.0% YoY), while the FY2025 annual figure was 90.24%, up 173.0% from the prior year.
- Gross Margin for Q1 2026 stood at 90.72%, roughly flat from 90.97% in the prior quarter.
- The five-year high for Gross Margin was 96.9% in Q3 2023, with the low at 62.9% in Q3 2022.
- The 5-year median for Gross Margin is 88.77% (2024), against an average of 86.35%.
- The sharpest annual moves came in 2023 and 2024: Gross Margin surged 3400 bps in 2023, then sank 919 bps in 2024.
- Arcutis Biotherapeutics' Gross Margin stood at 83.62% in 2022, then gained by 13 bps to 94.89% in 2023, then dropped by 5 bps to 90.04% in 2024, then advanced by 1 bps to 90.97% in 2025, then dropped by 0 bps to 90.72% in 2026.
- Business Quant data shows ARQT's Gross Margin at 90.72% in Q1 2026, 90.97% in Q4 2025, and 91.25% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 91.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.58% |
| Mar 31, 2026 | 90.72% |
| Dec 31, 2025 | 90.97% |
| Sep 30, 2025 | 91.25% |
| Jun 30, 2025 | 90.81% |
| Mar 31, 2025 | 86.17% |
| Dec 31, 2024 | 90.04% |
| Sep 30, 2024 | 87.70% |
| Jun 30, 2024 | 88.77% |
| Mar 31, 2024 | 84.90% |
| Dec 31, 2023 | 94.89% |
| Sep 30, 2023 | 96.90% |
| Jun 30, 2023 | 83.73% |
| Mar 31, 2023 | 71.84% |
| Dec 31, 2022 | 83.62% |
| Sep 30, 2022 | 62.90% |